Health desk – 17 April 2021: WHO is convening a Guideline Development Group (GDG) to advise on updates needed to its recommendations on the treatment of drug susceptible tuberculosis (TB).
Drug susceptible TB affects approximately 7 million people annually. Approximately 85% of patients who take the six-month regimen will have a successful treatment outcome. In recent years, research efforts have been directed towards finding safe and effective shorter regimens. New evidence from a randomized controlled trial on a 4-month treatment regimen containing a fluoroquinolone and high dose rifapentine has recently become available to WHO. It is now time to review the evidence on shorter regimens again, to provide users worldwide with the most up to date evidence-informed guidance on how to treat drug susceptible TB.
The GDG meeting will be held online in late April 2021, in accordance with WHO requirements for the development of evidence-informed policy guidance. The updated recommendations will be released in 2021, as part of the treatment module of the WHO consolidated guidelines on tuberculosis.